PYPD News and Press, PolyPid Ltd. From 08/13/25

Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveil ed a Long-Acting GLP-1 Receptor Agonists Del...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

2025-08-12 09:05:45 ET More on PolyPid Seeking Alpha’s Quant Rating on PolyPid Historical earnings data for PolyPid Financial information for PolyPid Read the full article on Seeking Alpha For further details see: PolyPid appoints Nurit Twe...

PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (" PolyPid " or the " Company "), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer,...

PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial results and operational highlights before the...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid's product portfolio bey...

The Company Anticipates that with this Additional Funding, PolyPid’s Runway would be Extended beyond Anticipated U.S. Food and Drug Administration (“FDA”) Approval of D-PLEX₁₀₀ . The Company Recently Announced Successful Topline Re...

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery patients with large incisions. The double-blind trial of 798 patients ...

D-PLEX 100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions. The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of su...

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report to...